Trial Profile
Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Oct 2022 Planned End Date changed from 1 Nov 2022 to 31 Jan 2023.
- 18 Jul 2022 Planned End Date changed from 1 Sep 2022 to 1 Nov 2022.